Find out what’s happening with Dr. Wang’s local and national clinical trials for leukemia treatment.
Crenolanib combination therapy
Crenolanib is a potent type I FLT3 inhibitor active against FLT3- ITD, TKD and variant mutations. Long-term outcomes of a recent phase 2 trial (NCT02283177) of crenolanib combined with 7+3 induction and consolidation in adults with newly diagnosed FLT3 mutant AML demonstrate high response rates (CRc 86%).
A phase 3 trial (NCT03258931) randomizing patients with newly diagnosed FLT3 mutant AML to crenolanib vs midostaurin with 7+3 is ongoing.
Press release2022 ASCO presentation
We believe that addition of this next-generation FLT3 inhibitor to conventional chemotherapy could significantly improve outcomes and become the new standard of care for patients with FLT3-mutant AML.Eunice Wang, MD
Frontline treatment with gilteritinib
For newly diagnosed AML patients unable to receive intensive induction chemotherapy, survival is limited, and therapy options are few. Gilteritinib is an oral FLT3 inhibitor approved as a single agent for the treatment of patients with FLT3-mutated (FLT3mut+) relapsed or refractory AML.
The LACEWING trial (NCT02752035) investigated the safety, tolerability and effectiveness of gilteritinib plus azacitidine chemotherapy in patients with FLT3-mutated relapsed/refractory AML.
Active clinical trials
Connect with the Wang Lab
Department of Immunology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263